Safety Study of Repeat Doses of SUSTOL in Adults
← catalyst calendarSponsored by Heron Therapeutics (industry) · HRTX — their whole pipeline →.
Phase
Phase 4
Status
Unknown status
Study type
Interventional
Design
Na · None · Prevention
Enrollment
300estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-06 | actual | When the study began enrolling |
| Primary completion | Oct 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2022-06-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2023-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chemotherapy-Induced Nausea and Vomiting (CINV)
Intervention
- Drug: SUSTOL — also filed as Granisetron extended-release injection for subcutaneous use
Primary outcome
what the primary-completion date above is the date OFNumber of subjects with potential impact of subject-reported ISRs on ADL in adult subjects with cancer administered SUSTOL.
measured 14 days
Permalink · HRTX's whole pipeline · Catalyst calendar · Every registered study · What changed